Role of <i>eIF4E</i> on epithelial‐mesenchymal transition, invasion, and chemoresistance of prostate cancer cells

Liu, Xujie; Vaidya, Amita; Sun, Da; Zhang, Yan; Ayat, Nadia; Schilb, Andrew; Lü, Zheng Rong

doi:10.1002/cac2.12011

Cited by 5 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PC3 prostate cancer cells are a PSMA-negative and highly aggressive cell line that is commonly used as an aggressive tumor model in prostate cancer research. Interestingly, PC3-DR cells, which were generated from PC3 cells by acquired resistance to 200 nM paclitaxel, showed a different trend with decreased ability for invasion as compared to the parental PC3 cells . This observation exemplifies the heterogeneous natures of prostate cancer.…”

Section: Resultsmentioning

confidence: 90%

“…Interestingly, PC3-DR cells, which were generated from PC3 cells by acquired resistance to 200 nM paclitaxel, showed a different trend with decreased ability for invasion as compared to the parental PC3 cells. 38 This observation exemplifies the heterogeneous natures of prostate cancer. We investigated the ability of MRMI of EDB-FN for characterizing decreased invasiveness of the PC3-DR tumors in vivo.…”

Section: Mrmi Of Edb-fn For Monitoring Enzalutamide-resistance Of Pro...mentioning

confidence: 77%

See 1 more Smart Citation

MR Molecular Imaging of Extradomain-B Fibronectin for Assessing Progression and Therapy Resistance of Prostate Cancer

Vaidya,

Shankardass,

Buford

et al. 2024

Chemical & Biomedical Imaging

View full text Add to dashboard Cite

Accurate assessment and characterization of the progression and therapy response of prostate cancer are essential for precision healthcare of patients diagnosed with the disease. MRI is a clinical imaging modality routinely used for diagnostic imaging and treatment planning of prostate cancer. Extradomain B fibronectin (EDB-FN) is an oncofetal subtype of fibronectin highly expressed in the extracellular matrix of aggressive cancers, including prostate cancer. It is a promising molecular target for the detection and risk-stratification of prostate cancer with high-resolution MR molecular imaging (MRMI). In this study, we investigated the effectiveness of MRMI with an EDB-FN specific contrast agent MT218 for assessing the progression and therapy resistance of prostate cancer. Low grade LNCaP prostate cancer cells became an invasive phenotype LNCaP-CXCR2 with elevated EDB-FN expression after acquisition of the C-X-C motif chemokine receptor 2 (CXCR2). MT218-MRMI showed brighter signal enhancement in LNCaP-CXCR2 tumor xenografts with a ∼2-fold contrast-to-noise (CNR) increase than in LNCaP tumors in mice. Enzalutamide-resistant C4-2-DR prostate cancer cells were more invasive, with higher EDB-FN expression than parental C4-2 cells. Brighter signal enhancement with a ∼2-fold CNR increase was observed in the C4-2-DR xenografts compared to that of C4-2 tumors in mice with MT218-MRMI. Interestingly, when invasive PC3 prostate cancer cells developed resistance to paclitaxel, the drug-resistant PC3-DR cells became less invasive with reduced EDB-FN expression than the parental PC3 cells. MT218-MRMI detected reduced brightness in the PC3-DR xenografts with more than 2-fold reduction of CNR compared to PC3 tumors in mice. The signal enhancement in all tumors was supported by the immunohistochemical staining of EDB-FN with the G4 monoclonal antibody. The results indicate that MRMI of EDB-FN with MT218 has promise for detection, risk stratification, and monitoring the progression and therapy response of invasive prostate cancer.

show abstract

Section: Resultsmentioning

confidence: 90%

Section: Mrmi Of Edb-fn For Monitoring Enzalutamide-resistance Of Pro...mentioning

confidence: 77%

MR Molecular Imaging of Extradomain-B Fibronectin for Assessing Progression and Therapy Resistance of Prostate Cancer

Vaidya,

Shankardass,

Buford

et al. 2024

Chemical & Biomedical Imaging

View full text Add to dashboard Cite

show abstract

“…Therefore, our study is the first time to link CYFIP1 with the immune microenvironment of PAH, which may provide a new way for CYFIP1 function research. Substantial evidence suggests that dysregulated expression of EIF4E is associated with 30% of human tumors, including head and neck cancer ( 54 ), endometrial cancer ( 55 ) and prostate cancer ( 56 ). This improves understanding of the role of EIF4E in cancer biology.…”

Section: Discussionmentioning

confidence: 99%

Analysis of m7G methylation modification patterns and pulmonary vascular immune microenvironment in pulmonary arterial hypertension

Wang

Zhang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundM7G methylation modification plays an important role in cardiovascular disease development. Dysregulation of the immune microenvironment is closely related to the pathogenesis of PAH. However, it is unclear whether m7G methylation is involved in the progress of PAH by affecting the immune microenvironment.MethodsThe gene expression profile of PAH was obtained from the GEO database, and the m7G regulatory factors were analyzed for differences. Machine learning algorithms were used to screen characteristic genes, including the least absolute shrinkage and selection operator, random forest, and support vector machine recursive feature elimination analysis. Constructed a nomogram model, and receiver operating characteristic was used to evaluate the diagnosis of disease characteristic genes value. Next, we used an unsupervised clustering method to perform consistent clustering analysis on m7G differential genes. Used the ssGSEA algorithm to estimate the relationship between the m7G regulator in PAH and immune cell infiltration and analyze the correlation with disease-characteristic genes. Finally, the listed drugs were evaluated through the screened signature genes.ResultsWe identified 15 kinds of m7G differential genes. CYFIP1, EIF4E, and IFIT5 were identified as signature genes by the machine learning algorithm. Meanwhile, two m7G molecular subtypes were identified by consensus clustering (cluster A/B). In addition, immune cell infiltration analysis showed that activated CD4 T cells, regulatory T cells, and type 2 T helper cells were upregulated in m7G cluster B, CD56 dim natural killer cells, MDSC, and monocyte were upregulated in the m7G cluster A. It might be helpful to select Calpain inhibitor I and Everolimus for the treatment of PAH.ConclusionOur study identified CYFIP1, EIF4E, and IFIT5 as novel diagnostic biomarkers in PAH. Furthermore, their association with immune cell infiltration may facilitate the development of immune therapy in PAH.

show abstract

“…The epithelial-mesenchymal transition (EMT) has important roles in all stages of cancer progression from initiation, invasion and metastasis to colonization [5][6][7]. EMT is executed by EMT-activating transcription factors (EMT-TFs), consisting mainly of the Snail, Twist and ZEB families [8].…”

Section: Introductionmentioning

confidence: 99%

NXN suppresses metastasis of hepatocellular carcinoma by promoting degradation of Snail through binding to DUB3

Zuo

Qiu

et al. 2022

Cell Death Dis

View full text Add to dashboard Cite

The poor prognosis of hepatocellular carcinoma (HCC) could be attributed to its high metastasis rate. Here, we report the role of nucleoredoxin (NXN), a multifunctional redox-active protein, in HCC metastasis. The expression of NXN in HCC tissues was measured by immunohistochemistry. The role of NXN on HCC proliferation was determined by CCK-8, EdU and colony formation assays in vitro and subcutaneous tumor formation model in vivo. Transwell and wound healing assays and tail vein injection model were performed to assess the function of NXN on HCC metastasis. Co-immunoprecipitation assay was performed to examine the interaction among NXN, Snail and DUB3. Our results showed that NXN was downregulated in HCC tissues compared to adjacent liver tissues. Patients with low NXN expression had shorter overall survival (OS) time (P < 0.001) than those with high NXN expression. Biologically, ectopic expression of NXN significantly inhibited the proliferation and metastasis of HCC cells both in vitro and in vivo by suppressing epithelial-mesenchymal transition (EMT). Mechanistically, NXN promoted the ubiquitin-proteasome-mediated degradation of Snail through interaction with DUB3. Further, depletion of Snail abolished NXN-inhibited cell proliferation and metastasis. In summary, NXN suppressed the proliferation and metastasis of HCC by inhibiting DUB3-mediated deubiquitylation of Snail protein. Our study demonstrates that NXN, DUB3 and Snail complex functioned as an important regulatory mechanism of HCC progression and indicates a potential therapeutic approach for the treatment of HCC metastasis.

show abstract

Role of eIF4E on epithelial‐mesenchymal transition, invasion, and chemoresistance of prostate cancer cells

Cited by 5 publications

References 11 publications

MR Molecular Imaging of Extradomain-B Fibronectin for Assessing Progression and Therapy Resistance of Prostate Cancer

MR Molecular Imaging of Extradomain-B Fibronectin for Assessing Progression and Therapy Resistance of Prostate Cancer

Analysis of m7G methylation modification patterns and pulmonary vascular immune microenvironment in pulmonary arterial hypertension

NXN suppresses metastasis of hepatocellular carcinoma by promoting degradation of Snail through binding to DUB3

Contact Info

Product

Resources

About